Drug facts
MoleculeDapagliflozin (Farxiga)
Generics already compete: 15 makers on the market. 30 A-rated products from 15 makers substitute at the counter.
Farxiga was first approved by the FDA on 01/08/2014 under NDA 202293; the application holder is Astrazeneca AB.
The latest NADAC for DAPAGLIFLOZIN 5 MG TABLET is $0.16 per unit (as of 10/28/2026).
Holder Astrazeneca ABApplication NDA 202293Approved 01/08/2014
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
5,449days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved01/08/2014
Exclusivity ends12/12/2027
Last patent10/01/2041
20152019202320272031203520392043
- Latest patent
- 10/01/2041Farxiga Orange Book
- Exclusivity
- 12/12/2027Farxiga Orange Book
02Competition
- Generics
- 15 generic makers Orange Book
- Staged generics
- 6 passed FDA review, awaiting market entry FDA
- First generic approved
- 04/06/2026 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Dapagliflozin profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.16 per unitDAPAGLIFLOZIN 5 MG TABLET, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Astrazeneca AB Orange Book
- Application
- NDA 202293 Orange Book
- First approved
- 01/08/2014 Orange Book
- Dosage forms
- tablet
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.